Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
180 participants
INTERVENTIONAL
2021-11-15
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
DMT310-003 Topical in the Treatment of Acne Vulgaris
NCT04106778
DMT210 Topical Gel in the Treatment of Acne Rosacea
NCT03003104
DMT310-009 Topical in the Treatment of Acne Vulgaris
NCT06090721
DMT310-001 Topical in the Treatment of Acne Vulgaris
NCT03536637
Azelaic Acid on Demodex Counts in Rosacea
NCT03035955
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Study Treatment 1
DMT310 Powder mixed with Hydrogen Peroxide
Topical Powder
Topical Powder mixed with diluent
Study Treatment 2
Placebo powder mixed with Hydrogen Peroxide
Placebo Topical Powder
Placebo Topical Powder mixed with diluent
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Topical Powder
Topical Powder mixed with diluent
Placebo Topical Powder
Placebo Topical Powder mixed with diluent
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Clinical diagnosis of moderate to severe papulopustular acne rosacea as determined by:
Investigator's Global Assessment (IGA) at Randomization score of 3 or 4. Patient has at least 15 inflammatory lesions on the face
Patient is willing to apply the Investigational Product as directed
Patient is willing and able to comply with the protocol
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dermata Therapeutics
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dermata Investigational Site
Austin, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DMT310-005
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.